Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.44 |
| ▸ | UCHL5 | Q9Y5K5 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799223 | 0.88 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1932766 | 0.85 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL16295121 | 0.83 | ATR (0.45) | KMOALOX5AP | |
| SCHEMBL1933631 | 0.82 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL12970648 | 0.81 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBTDP2 | |
| SCHEMBL938836 | 0.81 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL614711 | 0.80 | RET (0.61) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1933524 | 0.80 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBTDP2 | |
| SCHEMBL12554043 | 0.80 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBTDP2 | |
| SCHEMBL12506780 | 0.80 | TTK (0.57) | PIK3CGPIK3CDPIK3CATDP2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | claimed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | claimed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | claimed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | claimed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | claimed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| WO-2011063908-A1 | TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011063908-A1 | TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | PIK3C3, PIK3R3, PIK3R5 | PIK3CG 11/4885PIK3CD 6/4885PIK3CA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.